TABLE 1.

Demographic and clinical characteristics of patients in colistin and control groups

Characteristic	Colistin group (n = 31)	Control group (n = 64)	P value
Median (range) age (yr)	52 (10-72)	62 (3-82)	0.012
Sex (no. [%] of patients)
Male	22 (71)	40 (62)	0.42
Female	9 (29)	24 (38)
Underlying disease (no. [%] of patients)			0.033
Leukemia	20 (64)	24 (38)
Lymphoma/myeloma	4 (13)	9 (14)
Solid tumor	7 (23)	31 (48)
ICU stay (no. [%] of patients):
Within 30 days prior to infection	17 (55)	30 (47)	0.47
During infection	21 (68)	37 (58)	0.35
Median (range) APACHE II score	17 (11-27)	16 (7-32)	0.38
No. (%) of patients with:
Mechanical ventilation within prior mo	15 (48)	28 (44)	0.67
Hemodialysis within prior mo	8 (26)	8 (12)	0.10
Neutropenia within 30 days prior to infection	17 (55)	30 (47)	0.47
Median (range) duration (days) of neutropenia within 30 days prior to infection	(3-31)	(1-122)	0.89
Neutropenia during infection (no. [%] of patients)	14 (45)	24 (37)	0.48
Median (range) duration (days) of neutropenia during infection	(2-118)	(2-100)	0.32
No. (%) of patients with:
Pseudomonas infection or colonization (within prior year)	13 (42)	31 (48)	0.55
Polymicrobial infection	16 (52)	30 (47)	0.67
Hospital admission within 30 days prior to infection	30 (97)	39 (61)	0.0002
Nosocomial infection	27 (87)	41 (64)	0.02
Antibiotic resistance
Three classes	7 (23)	18 (28)	0.57
Four classes	7 (23)	26 (41)	0.083
Five classes	16 (52)	10 (16)	0.0002
Bacteremia	14 (45)	22 (34)	0.31
Pneumonia	17 (55)	30 (47)	0.47
UTI	0	7 (11)	0.056
Wound	0	5 (8)	0.17
Median (range) treatment duration (days)	20 (5-58)	20 (3-120)	0.53